SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: chirodoc who wrote (11021)11/13/1997 9:44:00 AM
From: Henry Niman  Read Replies (1) | Respond to of 32384
 
chirodoc, I'd say a LGND plug is a long shot unless they talk about the drug LGND's going to get (from SRGN?), or new ways to treat diabetes.



To: chirodoc who wrote (11021)11/13/1997 10:05:00 AM
From: Henry Niman  Read Replies (2) | Respond to of 32384
 
No mention of LGND, but Evista was discussed and possible $1/2 Billion is sales for the first year was also mentioned. Didn't want to talk about side effects (or narrow indication as predicted by CTSL). However, market should be substabtial and LLY is looking at combining with retinoid/rexinoid (maybe Targretin or LGD1268).
Also talked about wider indications for drugs in general.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News